2022 BPI East
September 27-30, Boston
Wuxi Advanced Therapies will be attending BPI East / Biotech Week Boston and Cell & Gene Therapy Manufacturing & Commericalization in Boston, MA from September 27-30.
Viral vector manufacture with integrated testing for cell and gene therapies
An integrated end-to-end service from discovery to commercialization of cell and gene therapies.
Talk to us about:
- Construct engineering and optimization,
- Cell line development, research grade or GMP plasmid supply
- Viral vector manufacture
- Proprietary TESSA™ technology and LentiVEX™ producer cell lines
- Cell therapy manufacture
- Integrated testing
Visit us in booth #716
Attend our technology workshop:
Date & Time: Thursday September 29th; 11:45am to 12:05pm EST
Location: Exhibition Hall
Navigating advanced therapy testing and the road to regulatory approval
Dr. Mike Stump, Executive Director of Testing Operations – WuXi Advanced Therapies
Cell and gene therapies have complex – and evolving – testing requirements that must be met to bring these exciting new treatments from bench to clinic, where they can benefit the patients who need them. Testing for cell and gene therapies poses scientific challenges in relation to the inherent variability of the starting material, the small volumes available for testing and rapid turn-around times required for autologous cell therapy testing in particular. But on top of these scientific challenges, the regulatory requirements are evolving too.
Working with an organization with a reputable testing service and expert regulatory support, such as WuXi Advanced Therapies, can help innovators navigate the challenging testing and regulatory landscape as smoothly as possible. Join WuXi Advanced Therapies presentation to see how we can partner together to travel the road towards successful approval.
Schedule a meeting with our experts
Bob Muschert
Vice President, Global Commercial Head
Linda Zhou
Business Development Manager
Mike Stump
Executive Director, Testing Operations
Request a meeting
"*" indicates required fields
AAVEX™ transient platform
Our AAVEX™ transient manufacturing platform uses OXGENE’s optimised AAVEX™ plasmids and a proprietary clonal suspension cell line to consistently deliver high yields of viral vector at all scales up to 200L. All the technologies and processes involved in viral vector manufacture on the AAVEX™ platform have been carefully validated and optimised for best performance, staff are pre-trained and all materials are in-stock. This results in a shorter end-to-end manufacturing and testing process, reduced manufacturing costs compared to a custom platform and accelerated time to market.
TESSA™ technology
Our proprietary TESSA™ technology exploits the natural partnership between AAV and adenovirus to maximise AAV production and quality, while preventing AAV contamination of the AAV material. At 200L scale, TESSA™-based AAV production results in 30-40 fold improvements in AAV yield compared to plasmid based AAV production methods, and achieves AAV packaging efficiency of over 95%. This next generation, plasmid free manufacturing process is safe, efficient and gives a significant cost of goods reduction.
AAVEX™ transient platform
Our AAVEX™ transient manufacturing platform uses OXGENE’s optimised AAVEX™ plasmids and a proprietary clonal suspension cell line to consistently deliver high yields of viral vector at all scales up to 200L. All the technologies and processes involved in viral vector manufacture on the AAVEX™ platform have been carefully validated and optimised for best performance, staff are pre-trained and all materials are in-stock. This results in a shorter end-to-end manufacturing and testing process, reduced manufacturing costs compared to a custom platform and accelerated time to market.
AAVEX™ transient platform
Our AAVEX™ transient manufacturing platform uses OXGENE’s optimised AAVEX™ plasmids and a proprietary clonal suspension cell line to consistently deliver high yields of viral vector at all scales up to 200L. All the technologies and processes involved in viral vector manufacture on the AAVEX™ platform have been carefully validated and optimised for best performance, staff are pre-trained and all materials are in-stock. This results in a shorter end-to-end manufacturing and testing process, reduced manufacturing costs compared to a custom platform and accelerated time to market.